Apogee Therapeutics (APGE) Capital Expenditures (2024 - 2025)
Apogee Therapeutics (APGE) reported Capital Expenditures of $62000.0 for Q4 2025, up 6300.0% year-over-year from $968.75 in Q4 2024, and down 98.72% quarter-over-quarter from $4.9 million in Q2 2025.
Apogee Therapeutics (APGE) Capital Expenditures (2024 - 2025) Analysis & Trends
Apogee Therapeutics (APGE) has 2 years of Capital Expenditures data on file, last reported at $62000.0 in Q4 2025.
- Capital Expenditures for Q4 2025 came in at $62000.0, up 6300.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.1 million (up 346.79% YoY), and the FY2025 annual result was $5.1 million, up 346.79% from the prior year.
- Capital Expenditures retreated to $62000.0 in Q4 2025 per APGE's latest filing, from $4.9 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $4.9 million in Q2 2025 and troughed at -$1000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Jun 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 351,000.00 |
| Mar 31, 2024 | 351,000.00 |